Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases

Biomaterials

Volumn 34, Issue 4, 2013, Pages 1270-1280

  Malhotra, Meenakshi ^a   Tomaro Duchesneau, Catherine ^a   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Chitosan; Gene delivery; Nanoparticles; PEG; SiRNA; TAT

Indexed keywords

ALZHEIMER'S; CELL-PENETRATING PEPTIDE; CHEMOSELECTIVE; CHITOSAN NANOPARTICLES; GENE DELIVERY; HYDROXYL GROUPS; IN-VITRO; NEURONAL CELL; SIRNA; SIRNA DELIVERY; TAT; THERAPEUTIC MOLECULES;

CHITOSAN; FOURIER TRANSFORM INFRARED SPECTROSCOPY; GENE TRANSFER; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PEPTIDES; POLYETHYLENE GLYCOLS; POLYMERS; RNA; TRANSCRIPTION; TRANSMISSION ELECTRON MICROSCOPY;

SYNTHESIS (CHEMICAL);

ATAXIN 1; CHITOSAN; HYDROXYL GROUP; MACROGOL; NANOPARTICLE; PEPTIDE; SMALL INTERFERING RNA; TAT PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE TARGETING; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; TASK PERFORMANCE;

ANIMALS; CHITOSAN; GENE PRODUCTS, TAT; HUMANS; NANOCAPSULES; NEURODEGENERATIVE DISEASES; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING; TRANSFECTION; TREATMENT OUTCOME;

EID: 84870307914     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.013     Document Type: Article

References (43)

1. Bettencourt C., Lima M. Machado-joseph disease: from first descriptions to new perspectives. Orphanet J Rare Dis 2011, 6:35.
2. Prakash S., Malhotra M. Recent advancements in targeted delivery of therapeutic molecules in neurodegenerative disease-spinocerebellar ataxia-opportunities and challenges. Drug Target Insights 2008, 3:99-117.
3. Di Prospero N.A., Baker A., Jeffries N., Fischbeck K.H. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomized, placebo-controlled trial. Lancet Neurol 2007, 6:878-886.
4. Xia H., Mao Q., Eliason S.L., Harper S.Q., Martins I.H., Orr H.T., et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004, 10:816-820.
5. Dorn G., Patel S., Wotherspoon G., Hemmings-Mieszczak M., Barclay J., Natt F.J., et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004, 32:e49.
6. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-3370.
7. Zhang Y., Zhang Y.F., Bryant J., Charles A., Boado R.J., Pardridge W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004, 10:3667-3677.
8. Bhoumik A., Jones N., Ronai Z. Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. PNAS 2004, 101:4222-4227.
9. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003, 51:90-105.
10. Lu P.Y., Xie F., Woodle M.C. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005, 54:117-142.
11. Arai K., Kineemaki T., Fujita T. Toxicity of chitosan. Bull Tokai Reg Fish Res Lab 1968, 56:89-94.
12. Yamamoto H., Amaike M. Biodegradation of cross-linked chitosan gels by microorganisms. Macromolecules 1997, 30:3936-3937.
13. Risbud M.V., Bhonde R.R. Polyacrylamide-chitosan hydrogels: in vitro biocompatibility and sustained antibiotic release studies. Drug Deliv 2000, 7:69-75.
14. Working P.K., Newman M.S., Johnson J., Cornacoff J.B. Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives. Polyethylene glycol chemistry and biological applications 1997, 45. American Chemical Society, Washington DC. J.M. Harris, S. Zalipsky (Eds.).
15. Sugimoto M., Morimoto M., Sashiwa H., Saimoto H., Shigemasa Y. Preparation and characterization of water-soluble chitin and chitosan derivatives. Carbohydr Polym 1998, 36:49-59.
16. Ouchi T., Nishizawa H., Ohya Y. Aggregation phenomenon of peg-grafted chitosan in aqueous solution. Polymer 1998, 39:5171-5175.
17. Lebouc F., Dez I., Desbrieres J., Picton L., Madec P.J. Different ways for grafting ester derivatives of poly(ethylene glycol) onto chitosan: related characteristics and potential properties. Polymer 2005, 46:639-651.
18. Kircheis R., Kichler A., Wallner G., Kursa M., Ogris M., Felzmann T., et al. Coupling of cell-binding ligands to polyethyleneimine for targeted gene delivery. Gen Ther 1997, 4:409-418.
19. Moore N.M., Sheppard C.L., Sakiyama-Elbert S.E. Characterization of a multifunctional peg-based gene delivery system containing nuclear localization signals and endosomal escape peptides. Acta Biomater 2009, 5:854-864.
20. Torchilin V.P., Rammohan R., Weissig V., Lev chenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001, 98:8786-8791.
21. Tseng Y.L., Liu J.J., Hong R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and TAT: a kinetic and efficacy study. Mol Pharmacol 2002, 62:864-872.
22. Kurita K., Ikeda H., Yoshida Y., Shimojoh M., Harata M. Chemoselective protection of amino groups of chitosan by controlled phthaloylation: facile preparation of a precursor useful for chemical modifications. Biomacromolecules 2002, 3:1-4.
23. Du Jian, Hsieh You-Lo Pegylation of chitosan for improved solubility and fiber formation via electrospinning. Cellulose 2007, 14:543-552.
24. Lin W.J., Chen M.H. Synthesis of multifunctional chitosan with galactose as a targeting ligand for glycoprotein receptor. Carbohydr Polym 2007, 67:474-480.
25. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999, 22:11-28.
26. Pardridge W.M. Peptide drug delivery to the brain 1991, 1-357. Raven Press, New York.
27. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004, 32:e149.
28. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006, 115:216-225.
29. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007, 104:15549-15554.
30. Inoue Y., Kurihara R., Tsuchida A., Hasegawa M., Nagashima T., Mori T., et al. Efficient delivery of siRNA using dendritic poly(l-lysine) for loss-of-function analysis. J Control Release 2008, 126:59-66.
31. Patil M.L., Zhang M., Betigeri S., Taratula O., He H., Minko T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 2008, 19:1396-1403.
32. Wissing S.A., Kayser O., Müller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004, 56:1257-1272.
33. Xia C.F., Zhang Y., Zhang Y., Boado R.J., Pardridge W.M. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007, 24:2309-2316.
34. Jones AR, Shusta EV. Antibodies and the blood-brain barrier. In: Therapeutic monoclonal antibodies: from bench to clinic. John Wiley & Sons, Inc. p. 483-502.
35. Sharma V, Piwnica-Worms D. Blood-brain barrier permeation peptides. US Patent No. US7,803,351 B2, 2010.
36. Pangestuti R., Kim S.K. Neuroprotective properties of chitosan and its derivatives. Mar Drugs 2010, 8:2117-2128.
37. Giglio E., Trapani A., Cafagna D., Sabbatini L., Cometa S. Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization. Anal Bioanal Chem 2011, 400:1997-2002.
38. Caban S., Capan Y., Couvreur P., Dalkara T. Preparation and characterization of biocompatible chitosan nanoparticles for targeted brain delivery of peptides. Methods Mol Biol 2012, 846:321-322.
39. Yoksan R., Matsusaki M., Akashi M., Chirachanchai S. Controlled hydrophobic/hydrophilic chitosan: colloidal phenomena and nanosphere formation. Colloid Polym Sci 2004, 282:337-342.
40. Kumar M.N.V.R., Muzzarelli R.A.A., Muzzarelli C., Sashiwa H., Domb A.J. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004, 104:6017-6084.
41. Gorochovceva N., MakuŠka R. Synthesis and study of water-soluble chitosan-O-poly(ethylene glycol) graft copolymers. Eur Polym J 2004, 40:685-691.
42. Malhotra M., Lane C., Tomaro-Duchesneau C., Saha S., Prakash S. A novel method for synthesizing pegylated chitosan nanoparticles: strategy, preparation and in-vitro analysis. Int J Nanomedicine 2011, 6:485-494.
43. Malhotra M., Kulamarva A., Sebak S., Paul A., Bhathena J., Mirzaei M., et al. Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm 2009, 35:719-726.